Aptahem states that work on the drug candidate Apta-1 is now focused on defining patient selection, study design and decision-making material ahead of the next clinical stage. This is stated in a newsletter from the research company.
Apta-1 has completed Phase 1 with a good safety and tolerability profile. The company is now working together with Professor Folke Sjöberg on the prerequisites for future patient studies, where patients with severe burns are a possible target group.
Aptahem also highlights that a test batch has been produced with approximately 99 percent purity through an improved manufacturing method. The company believes that better yield and more efficient use of materials could strengthen the basis for discussions with potential commercial partners.
